Degron Therapeutics
PrivateLast Round
Series A
Extension
May 14, 2026
Total Funding Raised
$132M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Degron Therapeutics operates in Healthcare & Life Sciences and is based in Shanghai. Its latest recorded funding round was a Series A Extension round in May 2026.
Degron Therapeutics is a biotechnology company developing a new class of small-molecule medicines that target previously undruggable targets using its proprietary molecular glue-based targeted protein degradation drug discovery platform.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Degron Therapeutics Comparables
Compare Degron Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Proxygen | 92% | |
| SEED Therapeutics | 90% | |
| Neomorph | 89% |
For institutional investors. Book with your work email.
Degron Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | May 14, 2026 | ||||
| Strategic | May 23, 2024 | ||||
| Series A | Jun 9, 2022 | ||||
| Seed | Apr 1, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Degron Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| DYEE Capital | Series A |
| Fengchuan Capital | Series A |
| Longmen Capital | Series A |
| Co-Win Ventures | Series A, Seed |
| YuanBio Venture Capital | Series A, Seed |
| Baidu Ventures | Series A |
| GF Xinde Investment Management | Series A Extension |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Grew 17% QoQ, from 24 to 28 employees.
- Aug 20, 2026
Monthly visitors increased 47% MoM.
For institutional investors. Book with your work email.
Degron Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Degron Therapeutics's valuation, stock price, and market status.
Is Degron Therapeutics a public or private company?
Degron Therapeutics is a private company.
What is the current stock price of Degron Therapeutics?
Degron Therapeutics is a private company, so its shares have no public market price. Caplight tracks Degron Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Degron Therapeutics worth (valuation)?
Valuation information for Degron Therapeutics is not publicly available.
Can I buy Degron Therapeutics stock?
Degron Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Degron Therapeutics's last funding round?
Degron Therapeutics's most recent funding round was Series A Extension on May 14, 2026.
Who are the main investors in Degron Therapeutics?
Key investors in Degron Therapeutics include Lapam Capital, Medfine Capital.
Will Degron Therapeutics IPO soon?
No public IPO plans have been announced for Degron Therapeutics.
How can I track Degron Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Degron Therapeutics's shares on secondary markets.